HealthQuill Immunotherapy
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or melanoma.
Pharma

Moderna, Merck’s personalised mRNA vaccine clears Phase 3 in melanoma

HQ Team August 20, 2026: Moderna’s stock more than doubled, surging as much as 177% intraday to $174.38 on Aug. 19, 2026, after.

Read More
Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for $2 billion, according to a statement. 
Drugs Medical Pharma

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion 

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for.

Read More
Daraxonrasib belongs to a new class of therapies known as RAS(ON) multi-selective inhibitors.
Drugs Health

New pancreatic cancer vaccine shows promise in preventing recurrence in trial-1

HQ Team August 12, 2025: A new study published in the journal Nature Medicine has shown promising results for an experimental vaccine, ELI-002.

Read More
Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.
Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

Read More
An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the patients with a fatal form of brain cancer.
Drugs Health Pharma

Gilead unit’s experimental therapy shrink brain tumours by 62%

HQ Team June 2, 2025: An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the.

Read More
mrnA cancer vaccine
Drugs Medical

Tailored kidney cancer trial vaccine shows recurrence-free survival

HQ Team  February 6, 2025: A phase I clinical trial has shown that personalized cancer vaccines targeting driver mutations can lead to 100%.

Read More
Alzheimer's
Health Medical

Brain shrinkage from Alzheimer’s therapy is desirable, not harmful: Study

Bharti Jayshankar December 2, 2024: A recent study by University College London (UCL) has revealed that the decrease in brain volume observed in.

Read More
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.
Drugs Health Medical

New CAR T-cell therapy offers hope for children with aggressive blood cancer

HQ Team October 14, 2024: Children with aggressive blood cancer may soon have access to a new treatment, CAR T-cell therapy, targeting T-cell.

Read More
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of overall survival in patients previously treated for a type of metastatic colorectal cancer. 
Drugs Health Pharma

Merck’s trial drug combination for colorectal cancer fails main goal

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.

Read More
Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug Administration.
Drugs Health Pharma

Merck’s advanced lung cancer drug gets US drug regulator’s nod

Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug.

Read More